The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Thrombolysis for acute ischaemic stroke
Open accessAbstract
BACKGROUND: Most strokes are due to blockage of an artery in the brain by a blood clot. Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage has occurred and improve recovery after stroke in some people. Thrombolytic drugs, however, can also cause serious bleeding in the brain, which can be fatal. One drug, recombinant tissue plasminogen activator (rt-PA), is licensed for use in selected patients within 4.5 hours of stroke in Europe and within three hours in the USA. There is an upper age limit of 80 years in some countries, and a limitation to mainly non-severe stroke in others. Forty per cent more data are available since this review was last updated in 2009. OBJECTIVES: To determine whether, and in what circumstances, thrombolytic therapy might be an effective and safe treatment for acute ischaemic stroke. SEARCH METHODS: We searched the Cochrane Stroke Group Trials Register (last searched November 2013), MEDLINE (1966 to November 2013) and EMBASE (1980 to November 2013). We also handsearched conference proceedings and journals, searched reference lists and contacted pharmaceutical companies and trialists. SELECTION CRITERIA: Randomised trials of any thrombolytic agent compared with control in people with definite ischaemic stroke. DATA COLLECTION AND ANALYSIS: Two review authors applied the inclusion criteria, extracted data and assessed trial quality. We verified the extracted data with investigators of all major trials, obtaining additional unpublished data if available. MAIN RESULTS: We included 27 trials, involving 10,187 participants, testing urokinase, streptokinase, rt-PA, recombinant pro-urokinase or desmoteplase. Four trials used intra-arterial administration, while the rest used the intravenous route. Most data come from trials that started treatment up to six hours after stroke. About 44% of the trials (about 70% of the participants) were testing intravenous rt-PA. In earlier studies very few of the participants (0.5%) were aged over 80 years; in this update, 16% of participants are over 80 years of age due to the inclusion of IST-3 (53% of participants in this trial were aged over 80 years). Trials published more recently utilised computerised randomisation, so there are less likely to be baseline imbalances than in previous versions of the review. More than 50% of trials fulfilled criteria for high-grade concealment; there were few losses to follow-up for the main outcomes.Thrombolytic therapy, mostly administered up to six hours after ischaemic stroke, significantly reduced the proportion of participants who were dead or dependent (modified Rankin 3 to 6) at three to six months after stroke (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.78 to 0.93). Thrombolytic therapy increased the risk of symptomatic intracranial haemorrhage (OR 3.75, 95% CI 3.11 to 4.51), early death (OR 1.69, 95% CI 1.44 to 1.98; 13 trials, 7458 participants) and death by three to six months after stroke (OR 1.18, 95% CI 1.06 to 1.30). Early death after thrombolysis was mostly attributable to intracranial haemorrhage. Treatment within three hours of stroke was more effective in reducing death or dependency (OR 0.66, 95% CI 0.56 to 0.79) without any increase in death (OR 0.99, 95% CI 0.82 to 1.21; 11 trials, 2187 participants). There was heterogeneity between the trials. Contemporaneous antithrombotic drugs increased the risk of death. Trials testing rt-PA showed a significant reduction in death or dependency with treatment up to six hours (OR 0.84, 95% CI 0.77 to 0.93, P = 0.0006; 8 trials, 6729 participants) with significant heterogeneity; treatment within three hours was more beneficial (OR 0.65, 95% CI 0.54 to 0.80, P < 0.0001; 6 trials, 1779 participants) without heterogeneity. Participants aged over 80 years benefited equally to those aged under 80 years, particularly if treated within three hours of stroke. AUTHORS' CONCLUSIONS: Thrombolytic therapy given up to six hours after stroke reduces the proportion of dead or dependent people. Those treated within the first three hours derive substantially more benefit than with later treatment. This overall benefit was apparent despite an increase in symptomatic intracranial haemorrhage, deaths at seven to 10 days, and deaths at final follow-up (except for trials testing rt-PA, which had no effect on death at final follow-up). Further trials are needed to identify the latest time window, whether people with mild stroke benefit from thrombolysis, to find ways of reducing symptomatic intracranial haemorrhage and deaths, and to identify the environment in which thrombolysis may best be given in routine practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–213 of 213
Feng, W., Vasquez, G., Suri, M. F. K., Lakshminarayan, K., & Qureshi, A. I. (2010) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2010.01.003 · Cited by 11
Long-Term Outcome as Function of Blood Pressure in Acute Ischemic Stroke and Effects of Thrombolysis
Mei, Y., Diener, H., Kaste, M., & Mau, J. (2007) · Cerebrovascular Diseases · doi:10.1159/000106981 · Cited by 10
NINDS Reanalysis Committee’s Reanalysis of the NINDS Trial
Mann, J. (2005) · Stroke · doi:10.1161/01.str.0000152953.71415.01 · Cited by 9
Fibrinolytic Therapy for Acute Stroke: The Spanish Experience
Dávalos, A. (1999) · Cerebrovascular Diseases · doi:10.1159/000047549 · Cited by 9
Stroking the Data: Re-analysis of the NINDS Trial
Magid, D. J., Naviaux, N. W., & Wears, R. L. (2005) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2005.01.030 · Cited by 9
Subgroups, Reanalyses, and Other Dangerous Things
Wears, R. L., Cooper, R. J., & Magid, D. J. (2005) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2005.05.007 · Cited by 8
Thrombolysis with alteplase after stroke: extending outcomes
Anderson, C. S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70149-2 · Cited by 7
Thrombolysis in acute stroke pooling project: a meta-analysis on individual patient data
Cornu, C., & Boutitie, F. (1999) · Journal of Clinical Neuroscience · doi:10.1016/s0967-5868(99)90596-9 · Cited by 7
Thrombolytic therapy. From myocardial to cerebral infarction
Candelise, L., Roncaglioni, M. C., Aritzu, E., Ciccone, A., Maggioni, A. P., & the MAST-I Group (1996) · Neurological Sciences · doi:10.1007/bf01995705 · Cited by 7
“Self-Fulfilling Prophecy” or Recognition Requires a Concept of Perception
von Kummer, R., & Hacke, W. (2000) · Stroke · doi:10.1161/01.str.31.1.231 · Cited by 4
Recruitment to trials of late thrombolysis: Lessons from the EXTEND study
Dagonnier, M., Howells, D. W., Donnan, G. A., & Dewey, H. M. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.10.033 · Cited by 4
Is Thrombolysis Useful for Acute Stroke Patients? The Experience of the MAST-I Study
The MAST-I Collaborative Group (1995) · Springer eBooks · doi:10.1007/978-4-431-68459-6_23 · Cited by 3
Dirks, M., Niessen, L. W., Huijsman, R., van Wijngaarden, J. D. H., Minkman, M. M. N., Franke, C. L., van Oostenbrugge, R. J., Koudstaal, P. J., & Dippel, D. W. J. (2007) · Cited by 2
Cited by
Jauch, E. C., Saver, J. L., Adams, H. P., Bruno, A., Connors, J. J. (., Demaerschalk, B. M., Khatri, P., McMullan, P. W., Qureshi, A. I., Rosenfield, K., et al. (2013) · Stroke · doi:10.1161/str.0b013e318284056a · Cited by 7,634
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008
(2008) · Cerebrovascular Diseases · doi:10.1159/000131083 · Cited by 2,489
Wahlgren, N., Ahmed, N., Dávalos, A., Ford, G. A., Grond, M., Hacke, W., Hennerici, M. G., Kaste, M., Kuelkens, S., Larrue, V., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60149-4 · Cited by 2,379
Methods to Explain the Clinical Significance of Health Status Measures
Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002) · Mayo Clinic Proceedings · doi:10.4065/77.4.371 · Cited by 1,500
Metadata
- Authors
- Wardlaw, J. M., Murray, V., Berge, E., & del Zoppo, G. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-07-29
- Volume
- 2016
- Issue
- 1
- Pages
- CD000213-CD000213
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2131499646
- Cited by
- 1,370
- References
- 213
- FWCI
- 61.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.